Proactiveinvestors recommends

Additional Information

Market:	ASX
Sector:	Aerospace
EPIC:	AMT
Latest Price:	0.22 (10.00% )
52-week High:	0.36
52-week Low:	0.15
Market Cap:	7.77M

1 year chart

1 day chart

Advanced Surgical Design & Manuf. Ltd
Advanced Surgical Design & Manufacture Limited (ASDM) is an Australia-based developer and manufacturer of prosthetic implants and medical devices. Its principal product is the Active Knee, a prosthetic implant, of which more than 4,000 have been implanted. This product is supported by a range of orthopedic accessories and surgical tools, and other orthopedic products. The Company provides integrated service to surgeons. It has built a patent and product development portfolio through collaborative research relationships with universities, companies and surgeon inventors that extends beyond orthopedics.

Advanced Computer Software expands homecare division with Cerrus Saturn acquisition

Tuesday, March 02, 2010

Advanced Computer Software (AIM: ASW) (ACS) has acquired Surrey-based software firm Cerrus Ltd for 0.37m in cash. The deal adds Cerrus' Saturn software suite, which is designed for community care and support management services.

According to ACS, Cerrus has annual recurring revenues of approximately 0.6m. The Saturn product has over 35,000 users, managing the delivery of care, resource management and organisational financial requirements across more than 60 community health and social care providers in the UK and Ireland.

This acquisition builds on ACS's previous acquisition in the homecare sector, in July 2009 the company bought StaffPlan in a cash and equity deal worth a combined 1.36m. ACS said the acquisition complements its Connect/Monitor products, and the integration of Saturn will extend the group's product portfolio in the social and community care market.

The acquisitive software company has been particularly busy in recent weeks, in February the company announced a massive 100m deal to buy Redac Holdings Ltd, owner of software group COA Solutions. Surrey-based COA provides software to the public and private sectors. Its principal products include systems for budgeting around patient pathways, data analysis, business intelligence, compliance, accounting and billing, procurement and document management.

The addition of the COA product portfolio, is expected to be immediately earnings enhancing and highly cash generative with strong recurring revenues. The payment for COA comprised cash and 55 million of new bank facilities - a term loan of 25 million and revolving credit of 30 million - which are committed for three and a half years and provided by HSBC (LSE: HSBA) and Royal Bank of Scotland (LSE: RBS).

COA posted revenues of 59.8 million in the full year to 31 March 2009 - of which more than 50 percent contracted recurring - , while EBITDA (earnings before interest, taxes, depreciation and amortisation) amounted to 12.3 million. The business has more than 1,600 corporate clients including Barclays (LSE: BARC), RBS (LSE: RBS), Santander LSE: BNC, NYSE: STD, Euronext: SANT), British Airways (LSE: BAY), Virgin, Trinity Mirror (LSE: TNI) and Specsavers.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.